BUDGET IMPACT ANALYSIS OF INTRODUCING FRUQUINTINIB FOR THE TREATMENT OF PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE

被引：0
|
作者：
Hernandez, L. G. [1 ]
Paly, V [1 ]
Li, S. [2 ]
Khanduri, P. [3 ]
Asfaw, A. A. [4 ]
Zou, D. [5 ]
机构：
[1] Takeda Pharmaceut America Inc, Lexington, MA USA
[2] Evidera, Toronto, ON, Canada
[3] Evidera, Waltham, MA USA
[4] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[5] Evidera, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE267
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [31] The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer
    Katrine Wallace
    Kelly Adamski
    Ashwini Pai
    Darya Rose
    Anita Chawla
    PharmacoEconomics, 2021, 39 : 231 - 241
  • [32] Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
    Li, Jin
    Qin, Shukui
    Xu, Rui-Hua
    Shen, Lin
    Xu, Jianming
    Bai, Yuxian
    Yang, Lei
    Deng, Yanhong
    Chen, Zhen-dong
    Zhong, Haijun
    Pan, Hongming
    Guo, Weijian
    Shu, Yongqian
    Yuan, Ying
    Zhou, Jianfeng
    Xu, Nong
    Liu, Tianshu
    Ma, Dong
    Wu, Changping
    Cheng, Ying
    Chen, Donghui
    Li, Wei
    Sun, Sanyuan
    Yu, Zhuang
    Cao, Peiguo
    Chen, Haihui
    Wang, Jiejun
    Wang, Shubin
    Wang, Hongbing
    Fan, Songhua
    Hua, Ye
    Su, Weiguo
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (24): : 2486 - 2496
  • [33] THE ECONOMIC IMPACT OF SWITCHING TO TRASTUZUMAB BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A CHINESE PAYER PERSPECTIVE
    Liu, S.
    Bozkaya, D.
    Brown, D.
    VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [34] BUDGET IMPACT ANALYSIS OF ZANUBRUTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY FROM THE PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, R.
    Yeh, Y. C.
    Yang, K.
    Gao, X.
    Balk, M.
    Tang, B.
    VALUE IN HEALTH, 2020, 23 : S434 - S434
  • [35] ESTIMATING THE BUDGET IMPACT OF INTRODUCING INDACATEROL IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE PUBLIC PAYER PERSPECTIVE IN SAO PAULO
    Suzuki, C.
    Silva, N. L.
    VALUE IN HEALTH, 2011, 14 (07) : A489 - A489
  • [36] BUDGET IMPACT ANALYSIS OF REGORAFENIB IN THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Zhu, S.
    Liu, J.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
  • [37] Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial
    Li, Jin
    Guo, Weijian
    Bai, Yuxian
    Deng, Yanhong
    Yang, Lei
    Chen, Zhendong
    Zhong, Haijun
    Xu, Ruihua
    Pan, Hongming
    Shu, Yongqian
    Yuan, Ying
    Zhou, Jianfeng
    Xu, Nong
    Liu, Tianshu
    Ma, Dong
    Wu, Changping
    Cheng, Ying
    Xu, Jianming
    Chen, Donghui
    Li, Wei
    Sun, Sanyuan
    Yu, Zhuang
    Cao, Peiguo
    Shen, Lin
    Chen, Haihui
    Wang, Shubin
    Wang, Hongbing
    Fan, Songhua
    Guo, Xiaojun
    Wang, Ning
    Han, Rubing
    Zhang, Bin
    Qin, Shukui
    ADVANCES IN THERAPY, 2020, 37 (11) : 4585 - 4598
  • [38] Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial
    Jin Li
    Weijian Guo
    Yuxian Bai
    Yanhong Deng
    Lei Yang
    Zhendong Chen
    Haijun Zhong
    Ruihua Xu
    Hongming Pan
    Yongqian Shu
    Ying Yuan
    Jianfeng Zhou
    Nong Xu
    Tianshu Liu
    Dong Ma
    Changping Wu
    Ying Cheng
    Jianming Xu
    Donghui Chen
    Wei Li
    Sanyuan Sun
    Zhuang Yu
    Peiguo Cao
    Lin Shen
    Haihui Chen
    Shubin Wang
    Hongbing Wang
    Songhua Fan
    Xiaojun Guo
    Ning Wang
    Rubing Han
    Bin Zhang
    Shukui Qin
    Advances in Therapy, 2020, 37 : 4585 - 4598
  • [39] BUDGET-IMPACT ANALYSIS (BIA) OF OBESITY FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL
    Busch, J.
    Reis Neto, J. P.
    VALUE IN HEALTH, 2019, 22 : S595 - S595
  • [40] BUDGET IMPACT ANALYSIS OF REGORAFENIB IN THE TREATMENT OF THIRD-LINE METASTATIC COLORECTAL CANCER IN THE PERSPECTIVE OF THE BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM (SHS)
    Bergamelli Ramos, N.
    Palhares, R.
    Cruz, A. T.
    Fanti, L.
    Lemmer, T.
    VALUE IN HEALTH, 2019, 22 : S77 - S78
12345